Iron (III) isomaltoside 1000

Expert Review of Hematology

Volumn 6, Issue 3, 2013, Pages 239-246

  MacE, Thomas A R ^a,b   Syed, Ahsan ^b   Bhandari, Sunil ^a,b  

^a UNIVERSITY OF HULL   (United Kingdom)

^b HULL ROYAL INFIRMARY   (United Kingdom)

Author keywords

anaemia; anemia; chronic kidney disease; dialysis; iron deficiency; iron deficiency anemia; iron isomaltoside; monofer; oxidative stress; renal

Indexed keywords

ANTIANEMIC AGENT; FERRIC CARBOXMALTOSE; FERRIC CARBOXYMALTOSE; FERRITIN; FERUMOXYTOL; HEMOGLOBIN; IRON DEXTRAN; IRON ISOMALTOSIDE; IRON SACCHARATE; MONOFER; REINSO; UNCLASSIFIED DRUG;

ANGINA PECTORIS; ARTHRALGIA; BLOOD PRESSURE; BODY WEIGHT; CHRONIC KIDNEY DISEASE; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG BLOOD LEVEL; DRUG COST; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; FERRITIN BLOOD LEVEL; HEART FAILURE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERHIDROSIS; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; INFLUENZA; IRON BLOOD LEVEL; IRON DEFICIENCY ANEMIA; IRON KINETICS; IRON THERAPY; KIDNEY INJURY; KIDNEY PROXIMAL TUBULE; MULTICENTER STUDY (TOPIC); NAUSEA; NEPHROTOXICITY; OXIDATIVE STRESS; PHARMACOKINETICS; PHARMACOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PULSE RATE; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; STAPHYLOCOCCAL BACTEREMIA; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ANEMIA, IRON-DEFICIENCY; CLINICAL TRIALS AS TOPIC; DISACCHARIDES; FERRIC COMPOUNDS; FERRITINS; HALF-LIFE; HEART FAILURE; HEMOGLOBINS; HUMANS; QUALITY OF LIFE; RENAL INSUFFICIENCY, CHRONIC;

EID: 84879396233     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/ehm.13.15     Document Type: Review

References (44)

1. McLean E, Cogswell M, Egli I, Wojdyla D, de Benoist B. Worldwide prevalence of anaemia, WHO Vitamin and Mineral Nutrition Information System, 1993-2005. Public Health Nutr. 12(4), 444-454 (2009).
2. WHO, UNICEF, UNU. Iron Defciency Anaemia: Assessment, Prevention and Control. A Guide for Programme Managers. World Health Organization, Geneva, Switzerland (2001).
3. Clark SF. Iron defciency anemia. Nutr. Clin. Pract. 23(2), 128-141 (2008).
4. Bhandari S. Risk factors and metabolic mechanisms in the pathogenesis of uraemic cardiac disease. Front. Biosci. 16, 1364-1387 (2011).
5. de Silva R, Rigby AS, Witte KK et al. Anemia, renal dysfunction, and their interaction in patients with chronic heart failure. Am. J. Cardiol. 98(3), 391-398 (2006).
6. Kidney disease: improving global outcomes (KDIGO) anemia work group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int. 2(4), S279-S335 (2012).
7. National Collaborating Centre for Chronic Conditions. In: Anaemia Management in Chronic Kidney Disease: National Clinical Guideline for Management in Adults and Children. Royal College of Physicians, London, UK (2006).
8. Gotloib L, Silverberg D, Fudin R, Shostak A. Iron defciency is a common cause of anemia in chronic kidney disease and can often be corrected with intravenous iron. J. Nephrol. 19 (2), 161-167 (2006).
9. Smrzova J, Balla J, Bárány P. Infammation and resistance to erythropoiesis-stimulating agents-what do we know and what needs to be clarifed? Nephrol. Dial. Transplant. 20(Suppl. 8), viii2-viii7 (2005).
10. Pfeffer MA, Burdmann EA, Chen CY et al.; TREAT Investigators. A trial of darbepoetin alfa in Type 2 diabetes and chronic kidney disease. N. Engl. J. Med. 361(21), 2019-2032 (2009).
11. Singh AK, Szczech L, Tang KL et al.; CHOIR Investigators. Correction of anemia with epoetin α in chronic kidney disease. N. Engl. J. Med. 355(20), 2085-2098 (2006).
12. Weiss G, Goodnough LT. Anemia of chronic disease. N. Engl. J. Med. 352(10), 1011-1023 (2005).
13. Chaplin S, Bhandari S. Oral iron: properties and current place in the treatment of anaemia. Prescriber 23, 12-18 (2012).
14. Melamed N, Ben-Haroush A, Kaplan B, Yogev Y. Iron supplementation in pregnancy-does the preparation matter? Arch. Gynecol. Obstet. 276(6), 601-604 (2007).
15. Bhandari S, Owda AK, Kendall RG et al. Red cell ferritin, a marker of iron defciency in hemodialysis patients. Ren. Fail. 19(6), 771-780 (1997).
16. Macdougall IC. Strategies for iron supplementation: oral versus intravenous. Kidney Int. Suppl. 69, S61-S66 (1999).
17. Albaramki J, Hodson EM, Craig JC, Webster AC. Parenteral versus oral iron therapy for adults and children with chronic kidney disease. Cochrane Database Syst. Rev. 1, CD007857 (2012).
18. Reinso® (ferumoxytol), prescribing information. Takeda Pharmaceuticals, Osaka, Japan (2012).
19. Danielson BG. Structure, chemistry, and pharmacokinetics of intravenous iron agents. J. Am. Soc. Nephrol. 15(Suppl. 2), S93-S98 (2004).
20. Wikström B, Bhandari S, Barany P et al. Iron isomaltoside 1000: a new intravenous iron for treating iron defciency in chronic kidney disease. J. Nephrol. 24(5), 589-596 (2011).
21. Hildebrandt PR, Bruun NE, Nielsen OW et al. Effects of administration of iron isomaltoside 1000 in patients with chronic heart failure: a pilot study. Transfus. Altern. Trans fus. Med. 11(4), 131-137 (2010).
22. Ganzoni AM. Intravenous iron-dextran: therapeutic and experimental possibilities. Schweiz. Med. Wochenschr. 100(7), 301-303 (1970).
23. Monofer® (iron isomaltoside 1000), prescribing information. Pharmacosmos, Holbaek, Denmark (2012).
24. Jahn MR, Andreasen HB, Fütterer S et al. A comparative study of the physicochemi-cal properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications. Eur. J. Pharm. Biopharm. 78(3), 480-491 (2011).
25. Nordfjeld K, Andreasen H, Thomsen LL. Pharmacokinetics of iron isomaltoside 1000 in patients with infammatory bowel disease. Drug Des. Devel. Ther. 6, 43-51 (2012).
26. Zager RA, Johnson AC, Hanson SY. Parenteral iron therapy exacerbates experimental sepsis. Kidney Int. 65(6), 2108-2112 (2004).
27. Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmén J. Update on adverse drug events associated with parenteral iron. Nephrol Dial. Transplant. 21(2), 378-382 (2006).
28. Kalra PA, Bock K, Meldal M. Iron isomaltoside 1000: a new high dose option for parenteral iron therapy. Port. J Nephrol Hypertens. 26(1), 13-24 (2012).
29. Ljungström KG, Renck H, Hedin H, Richter W, Wiholm BE. Hapten inhibition and dextran anaphylaxis. Anaesthesia 43(9), 729-732 (1988).
30. Kalra PA, Bhandari S, Thomsen LL. One visit iron repletion with iron isomaltoside 1000 (Monofer® ) in CKD and CHF patients. Presented at: ASN 43rd Annual Meeting. Denver, CO, USA, 16-21 November 2010.
31. Nath KA, Vercellotti GM, Grande JP et al Heme protein-induced chronic renal infammation: suppressive effect of induced heme oxygenase-1. Kidney Int. 59(1), 106-117 (2001).
32. Van Wyck DB. Labile iron: manifestations and clinical implications. J. Am. Soc. Nephrol. 15(Suppl. 2), S107-S111 (2004).
33. Toblli JE, Cao G, Oliveri L, Angerosa M. Comparison of oxidative stress and infammation induced by different intravenous iron sucrose similar preparations in a rat model. Infamm. Allergy Drug Targets 11(1), 66-78 (2012).
34. Zager RA. Parenteral iron compounds: potent oxidants but mainstays of anemia management in chronic renal disease. Clin. J. Am. Soc. Nephrol. 1(Suppl. 1), S24-S31 (2006).
35. Zager RA, Johnson AC, Hanson SY. Parenteral iron nephrotoxicity: potential mechanisms and consequences. Kidney Int. 66(1), 144-156 (2004).
36. Agarwal R, Vasavada N, Sachs NG, Chase S. Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int. 65 (6), 2279-2289 (2004).
37. Auerbach M, Ballard H, Trout JR et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J. Clin. Oncol. 22(7), 1301-1307 (2004).
38. Bhandari S, Naudeer S. Improving effciency and value in health care. Intravenous iron management for anaemia associated with chronic kidney disease: linking treatment to an outpatient clinic, optimizing service provision and patient choice. J. Eval. Clin. Pract. 14(6), 996-1001 (2008).
39. Ferinject® (ferric carboxymaltose), prescribing information. Vifor Pharmaceuticals, Glattbrugg, Switzerland (2011).
40. Auerbach M, Pappadakis JA, Bahrain H, Auerbach SA, Ballard H, Dahl NV. Safety and effcacy of rapidly administered (1 hour) one gram of low molecular weight iron dextran (INFeD) for the treatment of iron defcient anemia. Am. J. Hematol 86(10), 860-862 (2011).
41. Cooke M, Lamplugh A, Naudeer S, Edey M, Bhandari S. Effcacy and tolerability of accelerated-dose low-molecular-weight iron dextran (Cosmofer) in patients with chronic kidney disease. Am. J. Nephrol. 35(1), 69-74 (2012).
42. Venofer® (iron sucrose), prescribing information. Vifor Pharmaceuticals, Glattsbrugg, Switzerland (2011).
43. Bhandari S. Update of a comparative analysis of cost minimization following the introduction of newly available intravenous iron therapies in hospital practice. Ther. Clin. Risk Manag. 7, 501-509 (2011).
44. Sasu BJ, Cooke SC, Arvedson TL et al. Antihepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of infammation-induced anemia. Blood 115(17), 3616-3625 (2009).